Dr. Jordi Mestres (Girona, 1967) graduated in chemistry in 1990 from the Autonomous University of Barcelona (UAB) and received his doctorate in 1995 (specializing in computational chemistry) from the University of Girona, with short research stays at the Université de Paris-Sud (Paris, France; 1992) and Rice University (Houston, USA; 1993). Parallel to his research in the field of quantum chemistry, he headed towards the computational design of drugs, with a post-doctoral stay at the Pharmacia&Upjohn company (Kalamazoo, USA; 1996). In 1997, he joined the Organon company as a researcher (Oss, Holland; 1997-2000) and three years later was appointed as Director of Computational Medical Chemistry (Newhouse, United Kingdom; 2000-2003). In 2003 he returned to Barcelona and joined the Hospital del Mar Medical Research Institute as principal researcher (2003-2023) and as an associate professor at Pompeu Fabra University (2004-2022). He is the author of 166 publications and 10 patents.

He recently joined the Institute of Computational Chemistry and Catalysis (IQCC) at the University of Girona as a new visiting professor. His academic activity has always been linked to technology transfer activities. In 2006, he founded Chemotargets SL, a pioneer company in the Catalan biotech industry that has developed benchmark software in the field of pharmacology prediction and drug safety, today the softward is used by pharmaceutical and biotechnological companies around the world and by the American drug regulatory agency (FDA). In 2006 he received the Corwin Hansch award from the QSAR, Chemoinformatics and Modeling Society and in 2007 the first award for Technology Transfer from the Social Council of Pompeu Fabra University. In 2018 he was admitted as a Fellow of the Royal Society of Chemistry.

Welcome Jordi and good luck!

Girona, November 14th, 2023
For more info: ges.iqcc@udg.edu